Skip to main content
Year archive

ABL Bio Inc. — 2021 filings

All 51 regulatory filings released by ABL Bio Inc. (298380) in 2021, sourced directly from the official regulator.

51 Filings
2021 Period
2021 filings (51)
Filing Released Lang
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-12-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-12-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2021-12-22 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-12-15 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings
2021-12-15 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-11-23 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-11-12 Korean
분기보고서 (2021.09)
Interim / Quarterly Report 9M 2021
2021-11-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-11-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-10-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-10-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-09-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-08-31 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-08-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-08-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2021-08-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-08-17 Korean
반기보고서 (2021.06)
Interim / Quarterly Report H1 2021
2021-08-12 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL501의 국내 제1상 임상시험계획 (IND) 승인)
Regulatory Filings
2021-08-03 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-08-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-07-09 Korean
기타경영사항(특허권취득)(자율공시)(항 α-syn 항체 및 그 용도)
Regulatory Filings
2021-07-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-06-29 Korean
기타경영사항(특허권취득)(자율공시)(a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도)
Regulatory Filings
2021-06-07 Korean
투자판단관련주요경영사항(이중항체 항암제 ABL001의 제1a상 임상시험 결과)
Legal Proceedings Report
2021-05-27 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL501의 국내 제1상 임상시험계획 (IND) 신청)
Regulatory Filings
2021-05-20 Korean
투자판단관련주요경영사항(TRIGR Therapeutics에 대한 5개 항암제 후보 물질 기술이전 계약의 해지)
M&A Activity
2021-05-14 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Q1 2021
2021-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-04-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-04-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2021-03-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2021-03-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2021-03-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-03-31 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements
2021-03-30 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change
2021-03-30 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL111의 미국 FDA 제1상 임상시험계획 (IND) 승인)
Regulatory Filings
2021-03-29 Korean
사업보고서 (2020.12)
Audit Report / Information FY 2020
2021-03-16 Korean
주주총회소집공고
AGM Information
2021-03-16 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement
2021-03-16 Korean
감사보고서제출
Audit Report / Information FY 2020
2021-03-15 Korean
주주총회소집결의
AGM Information
2021-03-15 Korean
주주총회집중일개최사유신고
AGM Information
2021-03-15 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release FY 2020
2021-03-10 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL111의 미국 FDA 제1상 임상시험계획 (IND) 신청)
Regulatory Filings
2021-03-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-02-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2021-02-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2021-02-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release FY 2020
2021-02-10 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL503의 미국 FDA 제1상 임상시험계획 (IND) 승인)
Legal Proceedings Report
2021-01-29 Korean